###begin article-title 0
Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
RP105 is a Toll-like receptor homolog expressed on B cells, dendritic cells (DCs), and macrophages. We investigated the role of RP105 in the development of collagen-induced arthritis (CIA).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
CIA was induced in RP105-deficient DBA/1 mice and the incidence and arthritis index were analyzed. The cytokine production by spleen cells was determined. The functions of the DCs and regulatory T cells (Tregs) from RP105-deficient or control mice were determined by adding these cells to the lymph node cell culture. Arthritis was also induced by incomplete Freund's adjuvant (IFA) plus collagen or by injecting anti-collagen antibody and lipopolysaccharide.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
RP105-deficient mice showed accelerated onset of arthritis and increased severity. Interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha production by spleen cells from RP105-deficient mice was increased in comparison with that from wild-type mice. The DCs from RP105-deficient mice induced more IFN-gamma production, whereas Tregs from those mice showed less inhibitory effect against IFN-gamma production. RP105-deficient mice also showed more severe arthritis induced by collagen with IFA.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
These results indicate that RP105 regulates the antigen-presenting cell function and Treg development, which induced the attenuation of the cell-mediated immune responses and, as a result, suppressed the development of CIA.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 583 584 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 585 586 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 697 698 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1089 1090 1085 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1091 1092 1087 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1204 1205 1200 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1206 1207 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1271 1273 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1274 1276 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1291 1293 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1294 1296 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1337 1339 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1499 1501 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1502 1504 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 932 938 <span type="species:ncbi:9606">humans</span>
The Toll-like receptor (TLR) family is composed of pattern recognition receptors that recognize the pathogen-associated molecular patterns of microorganisms and trigger an innate immune response [1]. The TLRs are expressed mainly on macrophages and dendritic cells (DCs) and activate these cells after binding to their ligands. The activation of TLRs has been shown to induce proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1), and also to cause the upregulation of costimulatory molecules which activates the adaptive immune system [2,3]. Whereas the TLRs play a key role for host defense, they also play important roles in inflammatory diseases [4]. Rheumatoid arthritis (RA) is a chronic autoimmune and inflammatory disease characterized by synovial inflammation and destruction of cartilage and bone. Recently, TLRs have been shown to play an important role in arthritis both in humans and in experimental animal models. In RA, it has been shown that TLR2, TLR3, TLR4, and TLR7 are upregulated in the synovium and synovial macrophages [5-9]. Some of these TLRs are upregulated by proinflammatory cytokines and, in turn, have a costimulatory function [7,8]. The endogenous ligands of TLRs, such as heat shock proteins [10-12], hyaluronan [13,14], or degradation product of fibrinogen [15], are expressed in joints, and it is considered that they can activate DCs or macrophages via the TLR, thus leading to the progression of arthritis in joints [16,17].
###end p 11
###begin p 12
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 367 371 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 529 534 <span type="species:ncbi:10090">mouse</span>
In experimental animal models, the critical roles of the TLRs and their adaptor molecule myeloid differentiation factor 88 (MyD88) in the development of arthritis have been demonstrated in various models [18-22]. The data that the injection of TLR3 and TLR9 ligands into the joints induced arthritis [23,24] and that TLR9 ligand CpG immunization induces arthritis in rats [25] further support an arthritogenic role of TLRs. On the contrary, systemic TLR3 activation has been shown to suppress antibody-induced and TCR-transgenic mouse serum-induced arthritis [26], thus suggesting the different effect in arthritis between the local and systemic activation of TLRs.
###end p 12
###begin p 13
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
###xml 920 924 <span type="species:ncbi:10090">mice</span>
RP105, expressed on B cells, macrophages, and DCs, is a TLR homolog that lacks a conserved intracellular signaling domain (Toll-IL-1 receptor domain) and forms a complex with soluble protein MD-1 [27-29]. It has been shown that RP105 can provide proliferation and activation signals in B cells [28] and that B cells from RP105-deficient mice were hyporesponsive to TLR4 and TLR2 stimulation [30,31]. We have been working on RP105 on B cells in patients with autoimmune diseases, including systemic lupus erythematosus. We previously reported that B cells lacking RP105 expand in the peripheral blood of patients with systemic lupus erythematosus [32] and that these cells can produce anti-double-stranded DNA antibody [33]. On the other hand, Divanovic and colleagues [34] showed that RP105 directly interacts with TLR4 and negatively regulates TLR4 signaling by experiments using transfectant cells and RP105-deficient mice-derived DCs.
###end p 13
###begin p 14
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
In the present study, we investigated the role of RP105 in the development of collagen-induced arthritis (CIA) using RP105-deficient mice. CIA is an autoimmune inflammatory disease of the joints which is induced by immunization with type II collagen (CII). Our data show that RP105-deficient mice exhibit an accelerated onset of more severe arthritis, with an increased cytokine production of T cells and attenuated development of regulatory T cells (Tregs). These results suggest that RP105 plays a regulatory role in cell-mediated immunity and the development of CIA.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and experimental conditions
###end title 16
###begin p 17
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 216 220 216 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
RP105-deficient mice [30] were backcrossed into the DBA/1 background for six generations and genotyped by polymerase chain reaction using ear biopsy-derived DNA. In all experiments, only RP105-/-, RP105+/-, and RP105+/+ littermates were used. All mice were 12 to 16 weeks of age at the time of immunization. The animals were maintained at the Saga Medical School animal facility. The care of the animals was in accordance with the guidelines for animal experimentation of the Saga Medical School. All animal experiments were approved by the local ethical committee (University of Saga, numbers 07-015-4 and 07-015-5).
###end p 17
###begin title 18
Induction of collagen-induced arthritis
###end title 18
###begin p 19
###xml 216 243 214 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis </italic>
###xml 667 669 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 74 80 <span type="species:ncbi:9913">bovine</span>
###xml 183 186 <span type="species:ncbi:31658">CFA</span>
###xml 216 242 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 346 350 <span type="species:ncbi:10090">Mice</span>
###xml 406 412 <span type="species:ncbi:9913">bovine</span>
###xml 727 732 <span type="species:ncbi:10090">mouse</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
###xml 854 858 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
###xml 932 935 <span type="species:ncbi:31658">CFA</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 977 983 <span type="species:ncbi:9913">bovine</span>
Mice were immunized intradermally at the base of the tail with 150 mug of bovine CII (Cosmo Bio Co. Ltd., Tokyo, Japan) emulsified with an equal volume of complete Freund's adjuvant (CFA) containing 200 mug of H37RA Mycobacterium tuberculosis (Difco Laboratories Inc., now part of Becton Dickinson and Company, Franklin Lakes, NJ, USA) on day 0. Mice were boosted by an intradermal injection of 150 mug of bovine CII in incomplete Freund's adjuvant (IFA) (Difco Laboratories Inc) on day 21. Arthritis development was monitored by physical examination three times per week and the inflammation in each of the four paws was graded from 0 to 3, as described previously [35]. The four scores were added, with the maximum score per mouse being 12. The arthritis index was calculated by dividing the total score of the experimental mice by the number of total mice or arthritic mice. In the additional experiment, CIA was induced without CFA; the mice were immunized with 200 mug of bovine CII emulsified with IFA on days 0 and 21.
###end p 19
###begin title 20
Histology
###end title 20
###begin p 21
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
The ankle joints of the mice were excised 5 weeks after immunization and fixed in 10% buffered formalin, decalcified in 10% EDTA (ethylenediaminetetraacetic acid), embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The intensity of synovial hyperplasia, cellular infiltration, and pannus formation was examined and arthritis was graded in a blinded fashion on a scale of 0 to 4, as described previously [36].
###end p 21
###begin title 22
Measurement of the serum anti-CII antibody levels
###end title 22
###begin p 23
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 262 268 <span type="species:ncbi:9913">bovine</span>
###xml 364 368 <span type="species:ncbi:9925">goat</span>
###xml 374 379 <span type="species:ncbi:10090">mouse</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
The levels of serum antibodies to CII were measured by enzyme-linked immunosorbent assay (ELISA) as previously described [37]. Briefly, serial dilutions of serum samples were added to the microtiter plates (Maxisorp; Nunc, Roskilde, Denmark), coated with native bovine CII at 10 mug/mL, and incubated for 1 hour at 37degreesC. After washing, peroxidase-conjugated goat anti-mouse IgG1 or IgG2a (SouthernBiotech, Birmingham, AL, USA) was added and incubated for 1 hour at 37degreesC. Antibody binding was visualized using orthophenylenediamine (Sigma-Aldrich, St. Louis, MO, USA). A standard serum composed of a mixture of sera from the arthritic mice was added to each plate in serial dilutions and a standard curve was constructed. The standard serum was defined as 100 U and antibody titers of serum samples were calculated from the standard curve.
###end p 23
###begin title 24
Measurement of cytokine production by spleen cells
###end title 24
###begin p 25
###xml 234 236 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
Interferon-gamma (IFN-gamma), TNF-alpha, and IL-2 and IL-4 production was examined on day 28 in the spleen cells. The cells were resuspended in Dulbecco's modified Eagle's medium (DMEM) with 2% autologous mouse serum, seeded at 6 x 106 per wells in 24-well plates (Nunc), and stimulated with denatured CII (dCII) or Con A (Sigma-Aldrich) for 48 hours. The cytokines produced in the culture supernatant were measured by the cytometric beads assay system (BD Biosciences, San Jose, CA, USA) using FACSCalibur, except for the measurement of IL-17, which was done by ELISA (R&D Systems, Minneapolis, MN, USA).
###end p 25
###begin title 26
Preparation and functional analysis of splenic dendritic cells
###end title 26
###begin p 27
###xml 513 515 513 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 859 861 859 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 878 882 878 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 890 894 890 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 977 979 977 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 996 1000 996 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 894 898 <span type="species:ncbi:10090">mice</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
###xml 1094 1099 <span type="species:ncbi:10090">mouse</span>
The splenic DCs were purified by magnetic cell sorting using CD11c microbeads (Miltenyi Biotec, Auburn, CA, USA) in accordance with the manufacturer's instructions. Briefly, the spleens from two or three mice immunized with CII 8 days before were digested with collagenase D (Roche Diagnostics, Penzberg, Germany). The spleen cells were incubated with anti-CD16/32 antibody for blocking, labeled with CD11c magnetic-activated cell sorting beads, and applied to magnetic column. After washing the column, the CD11c+ DCs were obtained by flushing them out using a plunger. The resultant cell purity was greater than 92% by flow cytometry. The conventional DCs (cDCs) and plasmacytoid DCs (pDCs) were determined by staining with anti-CD11c plus anti-B220 and anti-PDCA-1 plus anti-B220 (Miltenyi Biotec). For functional analysis, the splenic DCs (50 or 12.5 x 104 cells) from RP105+/+ or RP105-/- mice were mixed with pooled adherent cell-removed lymph node cells (LNCs) (2.5 x 106 cells) from RP105+/- mice, which were immunized with CII 8 days before. The cells were resuspended in DMEM with 2% mouse serum and stimulated with dCII for 3 days. The IFN-gamma produced in the culture supernatant was measured using ELISA kits (Biosource International, Camarillo, CA, USA).
###end p 27
###begin title 28
Measurement of cytokine production by splenic dendritic cells
###end title 28
###begin p 29
###xml 26 30 26 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 39 43 39 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
The splenic DCs from RP105+/+ and RP105-/- mice separated as described were resuspended at 4 x 105 per well in 96-well microtiter plates and stimulated with various concentrations of lipopolysaccharide (LPS) (OB111; Sigma-Aldrich) for 24 hours. The cytokines produced in the culture supernatant were measured by the cytometric beads assay system (BD Biosciences) using FACSCalibur. The lower detection limit of cytokines was 3.0 pg/mL in these experiments.
###end p 29
###begin title 30
Preparation and functional analysis of regulatory T cells
###end title 30
###begin p 31
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 795 796 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 800 802 800 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1238 1239 1238 1239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1243 1245 1243 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1326 1330 1326 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1338 1342 1338 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1390 1392 1390 1392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1409 1413 1409 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1421 1425 1421 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1469 1471 1469 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1488 1492 1488 1492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 1342 1346 <span type="species:ncbi:10090">mice</span>
###xml 1425 1429 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1571 1576 <span type="species:ncbi:10090">mouse</span>
The Tregs were purified from the spleens by magnetic cell sorting using the CD4+CD25+ regulatory T-cell isolation kit (Miltenyi Biotec) in accordance with the manufacturer's instructions. Briefly, the spleens from three mice, immunized with CII 4 weeks before, were digested with collagenase D (Roche Diagnostics). The spleen cells were incubated with a biotin-labeled antibody cocktail and further incubated with anti-biotin microbeads and phycoerythrin-labeled anti-CD25 antibody. After washing, the cells were applied to the LD (lymphocyte depletion) column, and the T cells that passed through the column were collected. Thereafter, the T cells were incubated with anti-phycoerythrin microbeads, washed, and applied to the LS (lymphocyte separation) column. After washing the column, the CD4+CD25+ T cells were obtained by flushing them out with a plunger. The resultant cell purity was greater than 90% by flow cytometry, and the contaminating cells were mainly non-T non-B cells. Foxp3 staining was performed to compare the purity and its expression in recovered cells as well as whole spleen cells using fluorescein isothiocyanate-conjugated anti-Foxp3 antibody (eBioscience, San Diego, CA, USA). More than 95% of the recovered CD4+CD25+ T cells were positive for Foxp3, which was not different between cells from RP105+/+ or RP105-/- mice. For a functional analysis, Tregs (1.0 x 105 cells) from RP105+/+ or RP105-/- mice were added to the pooled LNCs (1.0 x 106 cells) from RP105+/- mice, which were immunized with CII 8 days before, resuspended in DMEM with 2% mouse sera, and stimulated with dCII or anti-CD3 antibody (BD Biosciences) for 3 days. The IFN-gamma produced in the culture supernatant was measured using ELISA kits (Biosource International).
###end p 31
###begin title 32
Induction of anti-CII antibody-induced arthritis
###end title 32
###begin p 33
###xml 100 104 100 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 113 117 113 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
Anti-CII antibody-induced arthritis was induced using a kit (Chondrex Inc., Redmond, WA, USA). RP105+/+ and RP105-/- mice were intravenously injected with 2 mg of a cocktail of monoclonal anti-CII antibodies. Three days later, 10 or 50 mug of LPS (Sigma-Aldrich) was injected intraperitoneally, and the mice were examined daily for signs of arthritis. In addition, the serum TNF-alpha levels after LPS challenge were determined. One hour after an intraperitoneal injection of LPS, the sera were collected and the TNF-alpha levels were measured using ELISA kits (Biosource International).
###end p 33
###begin title 34
Statistical analysis
###end title 34
###begin p 35
###xml 246 248 246 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
The analyses of the incidence of arthritis were performed using the chi-square analysis. The significance of the differences in the arthritic indexes, anti-CII antibody levels, and cytokine production was determined using either the Mann-Whitney U test or the Wilcoxon matched pairs test.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 130 134 130 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 143 147 143 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 253 257 253 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 383 387 383 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 447 451 447 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 576 580 576 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 589 593 589 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 797 801 797 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 849 853 849 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 1069 1073 1069 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1175 1179 1175 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1302 1306 1302 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1614 1616 1614 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 1711 1715 1711 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1829 1833 1829 1833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1842 1846 1842 1846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1885 1889 1885 1889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
###xml 1073 1077 <span type="species:ncbi:10090">mice</span>
###xml 1179 1183 <span type="species:ncbi:10090">mice</span>
###xml 1306 1310 <span type="species:ncbi:10090">mice</span>
###xml 1490 1494 <span type="species:ncbi:10090">mice</span>
###xml 1555 1559 <span type="species:ncbi:10090">mice</span>
###xml 1715 1719 <span type="species:ncbi:10090">mice</span>
###xml 1846 1850 <span type="species:ncbi:10090">mice</span>
###xml 1889 1893 <span type="species:ncbi:10090">mice</span>
RP105-deficient mice developed more severe collagen-induced arthritisTo examine the role of RP105 in the development of CIA, RP105+/+ and RP105-/- littermate mice were immunized with CII and monitored for signs of arthritis. As shown in Figure 1a, RP105-/- mice showed an earlier onset of disease, and a significantly higher incidence was observed from day 31 to day 42 than in RP105+/+ mice. After that period, the incidence of arthritis in RP105+/+ mice increased and no more differences were observed. The final rates of incidence of arthritis were 85.2% and 73.1% in RP105-/- and RP105+/+ mice, respectively. As shown in Figure 1b and 1c, the arthritis index increased gradually, thus indicating the chronic progression of the disease in a similar manner; however, the arthritis index in RP105-/- mice was significantly higher than that in RP105+/+ mice. To histologically determine the grade of arthritis, the ankle joints were excised, and the degree of cellular infiltration and synovial hyperplasia was examined. As shown in Figure 1d, the ankle joints of RP105-/- mice showed more severe synovitis, especially more inflammatory cell infiltration, than those of RP105+/+ mice at an early stage (day 35). We also compared the histology of arthritis at a late stage (7 to 8 weeks). Although RP105-/- mice showed a relatively severe degree of arthritis, the difference was not statistically significant (data not shown). To assess the humoral immune response to CII in RP105-deficient mice, the IgG1 and IgG2a anti-CII antibody levels in the sera of mice were determined on days 28 and 42. As shown in Figure 1e, although the anti-CII antibodies of both IgG subclasses seemed to be slightly higher in RP105-/- mice, they were not significantly different. The anti-CII antibody levels increased from day 28 to day 42 in RP105+/+ and RP105-/- mice. These results indicate that RP105-/- mice showed an accelerated onset of CIA and a more severe CIA and suggest that the RP105 molecule may therefore regulate the development of CIA.
###end p 37
###begin p 38
###xml 71 77 71 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a-d) </bold>
###xml 82 86 82 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 129 133 129 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 328 332 328 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 366 370 366 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 415 417 415 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 449 453 449 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 476 479 476 479 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 580 583 580 583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 610 613 610 613 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 626 628 626 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 641 643 641 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 675 679 675 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 698 700 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 707 710 707 710 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d)</bold>
###xml 760 764 760 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 807 811 807 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 862 864 862 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 890 894 890 894 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 968 972 968 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 990 994 990 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1064 1066 1062 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
The development of collagen-induced arthritis in RP105-deficient mice. (a-d) RP105+/+ (n = 26, 13 males and 13 females) and RP105-/- (n = 27, 13 males and 14 females) mice were immunized with type II collagen (CII), and signs of arthritis were monitored as described in Materials and methods. The incidence of arthritis in RP105-/- mice was higher than that in RP105+/+ mice between days 31 and 42 (*P < 0.05 and **P < 0.01 for comparison with RP105+/+ mice, chi-square test) (a). The disease severity, expressed as the mean arthritis index (and standard error) of the total mice (b) and of the arthritic mice (c), is shown (*P < 0.05 and **P < 0.01 for comparison with RP105+/+ mice, Mann-Whitney U test). (d) A histological examination was performed in RP105+/+ (n = 20, 10 males and 10 females) and RP105-/- (n = 23, 11 males and 12 females) mice at day 35 (*P < 0.05, chi-square test). (e) The anti-CII antibodies of IgG1 and IgG2a classes were measured from RP105+/+ (n = 18) and RP105-/- (n = 19) mice on days 28 and 42. Values are mean +/- standard error (*P < 0.001, Wilcoxon matched pairs test). AU, arbitrary units.
###end p 38
###begin title 39
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Interferon-gamma and tumor necrosis factor-alpha production by spleen cells was augmented in RP105-deficient mice
###end title 39
###begin p 40
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 282 286 282 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 385 389 377 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 395 397 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 408 410 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 543 531 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 552 556 544 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 569 574 561 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c, d</xref>
###xml 676 680 667 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 689 693 680 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
To analyze the antigen-specific responses of the spleen cells, the production of cytokines in response to CII was examined. CII-immunized mice were sacrificed on day 28, and the splenocytes were stimulated with dCII or ConA. As shown in Figure 2a and 2b, the spleen cells from RP105-/- mice produced a markedly larger amount of IFN-gamma and TNF-alpha in response to CII than did RP105+/+ mice (P < 0.01 and P < 0.05, respectively), but not in response to ConA. The production of IL-2 and IL-4 was not significantly different between RP105+/+ and RP105-/- mice (Figure 2c, d). In addition, IL-17 production from spleen cells in response to CII (50 mug/dL) was similar in RP105+/+ and RP105-/- mice (781.8 +/- 167.3 pg/mL and 840.3 +/- 236.0 pg/mL, n = 5).
###end p 40
###begin p 41
###xml 387 390 382 385 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 432 435 423 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 458 461 449 452 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 488 492 479 483 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 687 689 676 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 699 701 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 722 724 711 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 124 128 <span type="species:ncbi:10090">Mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
The cytokine production from spleen cells in response to denatured type II collagen (CII) and ConA in RP105-deficient mice. Mice were immunized with CII with complete Freund's adjuvant on day 0 and with CII with incomplete Freund's adjuvant on day 21. The spleen cells from day-28 mice were harvested and stimulated with CII or ConA (5 mug/mL) for 48 hours. Interferon-gamma (IFN-gamma) (a), tumor necrosis factor-alpha (TNF-alpha) (b), interleukin-4 (IL-4) (c), and interleukin-2 (IL-2) (d) produced in the culture supernatant were measured by cytometric beads assay. The results from two experiments (eight mice per experiment) are shown and expressed as the mean +/- standard error (*P < 0.05, **P < 0.01, Mann-Whitney U test).
###end p 41
###begin title 42
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
Dendritic cells from RP105-deficient mice induced more interferon-gamma production from lymph node cells than dendritic cells from wild-type mice
###end title 42
###begin p 43
###xml 280 284 280 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 292 296 292 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 365 369 365 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 429 433 429 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 499 503 495 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 597 598 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 604 605 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 637 638 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 644 645 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 702 694 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 711 715 707 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1013 1014 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
Because RP105 is not expressed on T cells, we speculated that the augmented cytokine production by spleen cells from RP105-deficient mice would be driven by antigen-presenting cells (APCs). To compare the function of DCs, the splenic DCs were purified from the CII-immunized RP105+/+ or RP105-/- mice, mixed with adherent cell-depleted LNCs from CII-immunized RP105+/- mice, and stimulated with dCII. As shown in Figure 3a, RP105-/- splenic DCs induced higher amounts of IFN-gamma by LNCs than RP105+/+ DCs at the higher cell numbers. Prepared splenic DCs consisted of greater than 70% cDCs (CD11c+, B220-) and less than 30% pDCs (PDCA-1+, B220+), and the subpopulation did not differ between RP105+/+ and RP105-/- mice (cDCs: 76% +/- 5% versus 75% +/- 2%). To evaluate DC function, we measured the cytokine production from DCs in response to LPS. The splenic DCs from the two types of mice produced similar amounts of TNF-alpha, IFN-gamma, and IL-6 and IL-10 in response to various concentrations of LPS (Figure 4).
###end p 43
###begin p 44
###xml 107 111 107 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 170 174 170 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 182 186 182 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 271 275 271 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 488 492 482 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 570 574 560 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 584 586 574 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 665 667 655 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 688 690 678 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 697 701 687 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 718 719 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 769 773 759 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 782 786 772 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 826 827 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 839 843 829 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1240 1242 1210 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
###xml 843 847 <span type="species:ncbi:10090">mice</span>
###xml 1223 1227 <span type="species:ncbi:10090">mice</span>
The functional analysis of dendritic cells (DCs) and regulatory T cells (Tregs) from RP105-deficient mice. (a) The splenic DCs from type II collagen (CII)-immunized RP105+/+ or RP105-/- mice were mixed with pooled adherent cells removed lymph node cells (LNCs) from RP105+/- mice, as described in Materials and methods. The cells were stimulated with denatured CII for 2 days and interferon-gamma (IFN-gamma) production was measured. Values are mean +/- standard error. The DCs from RP105-/- mice induced higher IFN-gamma production from LNCs than did the DCs from RP105+/+ at 50 x 104 cells. The summary of five experiments, using three mice per group, is shown (*P < 0.05, Mann-Whitney U test). (b) The Tregs (1 x 105) purified from the spleens of CII-immunized RP105+/+ and RP105-/- mice were mixed with pooled LNCs (1 x 106) from RP105+/- mice, which were immunized with CII 14 days before. The cells were stimulated with denatured CII (20 mug/mL) or anti-CD3 antibody (1 mug/mL) for 2 days and IFN-gamma production was measured. The percentage suppression (100 x [IFN-gamma without Tregs - IFN-gamma with Tregs]/IFN-gamma without Tregs) is shown. Values are mean +/- standard error of the six experiments, using three mice per group (*P < 0.05, Wilcoxon matched pairs test).
###end p 44
###begin p 45
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 195 199 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 208 212 208 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 380 383 376 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 414 417 406 409 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 440 443 432 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 472 476 464 468 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
The inflammatory cytokine production from splenic dendritic cells in response to lipopolysaccharide (LPS) in RP105-deficient mice. The dendritic cells (4 x 105) purified from the spleens of RP105+/+ and RP105-/- mice were stimulated with LPS at various concentrations for 24 hours. The supernatants were collected and the concentrations of tumor necrosis factor-alpha (TNF-alpha) (a), interferon-gamma (IFN-gamma) (b), interleukin-6 (IL-6) (c), and interleukin-10 (IL-10) (d) were measured. Values are mean +/- standard error of five experiments, using three mice per group.
###end p 45
###begin title 46
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Reduced suppressive function of regulatory T cells in response to CII but not to anti-CD3 from RP105-deficient mice
###end title 46
###begin p 47
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 316 317 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 323 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 361 363 361 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 378 380 378 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 420 424 420 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 433 437 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 593 595 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 627 631 619 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 656 660 646 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 860 864 844 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 872 876 856 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 926 930 910 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1135 1137 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1221 1225 1197 1201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1275 1279 1251 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1435 1439 1411 1415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1448 1452 1424 1428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1465 1467 1441 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1503 1507 1479 1483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 876 880 <span type="species:ncbi:10090">mice</span>
###xml 930 934 <span type="species:ncbi:10090">mice</span>
###xml 1225 1229 <span type="species:ncbi:10090">mice</span>
###xml 1279 1283 <span type="species:ncbi:10090">mice</span>
###xml 1452 1456 <span type="species:ncbi:10090">mice</span>
###xml 1507 1511 <span type="species:ncbi:10090">mice</span>
We investigated the function of Tregs from RP105-deficient mice because a recent report showed that the expression of MD1, a molecule that forms a complex with RP105, regulated the development of Tregs induced by LPS [38]. We first measured the number of Tregs in the spleen by flow cytometry. The percentages of CD4+CD25+ T cells among spleen cells and of CD25+ cells among CD4+ T cells were not different between RP105+/+ and RP105-/- mice (1.47% +/- 0.13% versus 1.33% +/- 0.18% and 11.6% +/- 0.9% versus 11.7% +/- 2.0%, respectively, n = 5). Similarly, the population of Foxp3-positive CD4+ T cells was not different (RP105+/+ 1.47% +/- 0.20% and RP105-/- 1.40% +/- 0.16%). Next, we examined the suppressive function of Tregs by measuring the IFN-gamma production by LNCs with or without the addition of Tregs. Tregs from the spleens of CII-immunized RP105+/+ or RP105-/- mice were mixed with LNCs from CII-immunized RP105+/- mice and stimulated with dCII or anti-CD3 antibody. From the preliminary experiment, we chose the LNC/Treg ratio for which the suppression of IFN-gamma production reached plateau level. As shown in Figure 3b, although Tregs suppressed the IFN-gamma production from LNCs, the Tregs from RP105-/- mice showed less suppression than those from RP105+/+ mice when they were stimulated with dCII. On the other hand, stimulation with anti-CD3 antibody induced comparable levels of suppression by Tregs from RP105+/+ and RP105-/- mice (Figure 3b). These results indicate that RP105-/- mice have attenuated antigen-induced suppressive function of Tregs or had a decreased number of CII-specific Tregs.
###end p 47
###begin title 48
###xml 16 20 <span type="species:ncbi:10090">mice</span>
RP105-deficient mice showed marginally augmented disease development in anti-CII antibody and lipopolysaccharide-induced arthritis
###end title 48
###begin p 49
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 240 244 240 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 253 257 253 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 424 428 423 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 437 441 436 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 659 663 657 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 674 678 672 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 772 777 769 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c, d</xref>
###xml 876 880 869 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 889 893 882 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1004 1006 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5e</xref>
###xml 1014 1018 1002 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1112 1114 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5f</xref>
###xml 1147 1151 1130 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1296 1304 1275 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 893 897 <span type="species:ncbi:10090">mice</span>
###xml 925 929 <span type="species:ncbi:10090">mice</span>
###xml 1018 1022 <span type="species:ncbi:10090">mice</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
To investigate the development of arthritis induced by LPS in RP105-deficient mice, we injected a cocktail of monoclonal anti-CII antibodies intravenously followed by the intraperitoneal injection of LPS. As shown in Figure 5a and 5b, RP105+/+ and RP105-/- mice showed similar development of arthritis after 2 mg of anti-CII antibodies followed by 50 mug of LPS 3 days later. The arthritis index did not differ between RP105+/+ and RP105-/- mice. We then examined the induction of arthritis with a decreased dose of LPS to test the response to LPS more concisely. Whereas the reduction of the dose of LPS to 10 mug decreased the severity of arthritis in RP105+/+ mice, RP105-/- mice still developed arthritis with a comparable severity as induced by 50 mug of LPS (Figure 5c, d). We compared the production of TNF-alpha after the intraperitoneal administration of LPS in RP105+/+ and RP105-/- mice. Although the two types of mice produced similar levels of TNF-alpha in response to 50 mug of LPS (Figure 5e), RP105-/- mice produced a significantly higher amount of TNF-alpha in response to 10 mug of LPS (Figure 5f). These data indicate that RP105-/- mice showed an enhanced production of TNF-alpha and arthritis development with a lower dose of LPS, suggesting a regulatory role of RP105 in the in vivo response to LPS.
###end p 49
###begin p 50
###xml 172 178 172 178 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a-d) </bold>
###xml 183 187 183 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 204 208 204 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 604 608 602 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 634 636 631 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 668 672 665 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 691 693 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 700 707 697 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e, f) </bold>
###xml 712 716 709 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 725 729 722 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 997 999 990 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1020 1022 1013 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
The development of anti-CII antibody and lipopolysaccharide (LPS)-induced arthritis and tumor necrosis factor-alpha production after LPS challenge in RP105-deficient mice. (a-d) RP105+/+ (n = 9) and RP105-/- (n = 9) mice were injected with a cocktail of monoclonal anti-CII antibodies intravenously and with 50 mug (a, b) or 10 mug (c, d) of LPS intraperitoneally 2 days later. The incidence of arthritis of paws (arthritic paws/total paws) (a, c) and disease severity, expressed as the mean arthritis index (and standard error) of mice (b, d), is shown. Arthritis index was significantly higher in RP105-/- mice with 10 mug of LPS (*P < 0.05 for comparison with RP105+/+ mice, Mann-Whitney U test). (e, f) RP105+/+ and RP105-/- mice were challenged intraperitoneally with 50 mug (e) (n = 10 and 11, respectively) or 10 mug (f) (n = 7 and 9, respectively) of LPS. The serum was collected 1 hour later and the tumor necrosis factor-alpha levels were measured. Values are mean +/- standard error. **P < 0.01, Mann-Whitney U test. CII, type II collagen.
###end p 50
###begin title 51
###xml 16 20 <span type="species:ncbi:10090">mice</span>
RP105-deficient mice developed more severe arthritis induced by incomplete Freund's adjuvant and CII
###end title 51
###begin p 52
###xml 80 84 80 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 137 150 137 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium</italic>
###xml 212 220 212 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 224 233 224 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 245 272 245 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis </italic>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 353 366 353 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium</italic>
###xml 499 503 499 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 512 516 512 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 549 553 549 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 808 812 808 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 172 175 <span type="species:ncbi:31658">CFA</span>
###xml 245 271 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 718 721 <span type="species:ncbi:31658">CFA</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 848 851 <span type="species:ncbi:31658">CFA</span>
We addressed the question of whether the enhanced arthritis development in RP105-/- mice was due to the enhanced response of TLRs to the Mycobacterium-containing adjuvant, CFA, because it has been shown that the in vivo and in vitro response to Mycobacterium tuberculosis is regulated by TLR2, TLR 4, and MyD88 [39-42]. To investigate the impact of the Mycobacterium-TLR interaction in the augmented arthritis development in RP105-deficient mice, we injected CII emulsified with IFA twice into RP105+/+ and RP105-/- mice. As shown in Figure 6, RP105-/- mice still showed a higher incidence of arthritis and more severe disease development, although they were not as prominent as those observed in CIA with the regular CFA-based induction. These data indicate that the augmented arthritis development in RP105-/- mice is not dependent solely on the CFA and suggest that other TLR ligands, presumably endogenous, might also play a role in this phenomenon.
###end p 52
###begin p 53
###xml 151 155 151 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 197 201 197 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 375 379 375 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 451 454 451 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 491 495 491 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 529 533 529 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 561 564 561 564 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 607 610 607 610 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 614 616 614 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 626 628 626 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 643 645 643 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 678 682 678 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 705 712 705 712 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c, d) </bold>
###xml 807 810 807 810 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 833 836 833 836 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d)</bold>
###xml 849 851 849 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 864 866 864 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 898 902 898 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 921 923 921 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
The development of collagen-induced arthritis induced with type II collagen (CII) and incomplete Freund's adjuvant (IFA) in RP105-deficient mice. RP105+/+ (n = 18, 11 males and 7 females) and RP105-/- (n = 22, 11 males and 11 females) mice were immunized with CII and IFA on days 0 and 21, and signs of arthritis were monitored. The arthritis incidence was shown as per body (a) and per paw (100 x [number of the arthritic paws/number of total paws]) (b). The incidence of arthritis in RP105-/- mice was higher than that in RP105+/+ mice on days 42, 66, and 73 (a) as was the per-paw incidence after day 38 (b). (*P < 0.05, **P < 0.01, and ***P < 0.001 for comparison with RP105+/+ mice, chi-square test) (c, d) The disease severity, expressed as the mean arthritis index (and standard error) of total mice (c) and of arthritic mice (d), is shown (*P < 0.05 and **P < 0.01 for comparison with RP105+/+ mice, Mann-Whitney U test).
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 72 76 72 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
In the present study, we showed augmented arthritis development in RP105-/- mice, with an increased production of IFN-gamma and TNF-alpha from spleen cells in response to CII. These results indicate that cell-mediated immune responses to immunized collagen are enhanced in RP105-deficient mice, thus suggesting RP105 to be a negative regulator of the immune system in this model.
###end p 55
###begin p 56
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 421 425 421 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 690 692 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 952 953 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1021 1023 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1187 1189 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
RP105 was originally found as a molecule that induces B-cell activation after its ligation, but it has been shown to be expressed also on macrophages and DCs. The role of RP105 on these cells, however, has not yet been clearly determined. Recently, Divanovic and colleagues [34] showed that the expression of RP105 by gene transfection suppressed TLR4 signaling in HEK293 cells and that DCs and the macrophages from RP105-/- mice produced a higher amount of cytokines in response to LPS. These data indicate that RP105 is an attenuator of TLR4-induced signaling [34]. We demonstrated here that DCs from RP105-deficient mice induced a larger amount of IFN-gamma production from LNCs (Figure 3a), thus indicating the augmented T-cell-activating function of DCs lacking RP105. On the other hand, we did not see any significant differences between DCs from RP105-deficient mice and those from control mice in cytokine production in response to LPS (Figure 4). These data are in contrast to those of Divanovic and colleagues [34]. The difference might be due to the purity of the LPS because the conventional LPS that we used might have been contaminated with a lipopeptide, the TLR2 ligand [34]. Alternatively, the different DC preparation, splenic DCs versus bone marrow-derived DCs, may have produced different results.
###end p 56
###begin p 57
###xml 490 498 486 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 533 542 529 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 570 571 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
In the anti-CII antibody and LPS-induced arthritis model, arthritis development and TNF-alpha production were enhanced in RP105-deficient mice when a reduced dose of LPS was administered. Although the difference in the arthritis index between wild-type and RP105-deficient mice was small in comparison with that when they were actively immunized, these results nevertheless support a regulatory role of RP105 in the development of arthritis induced by TLR ligands. On the other hand, these in vivo results cannot be explained by the in vitro data of splenic DCs (Figure 4). We therefore need to conduct more experiments using specific ligands and cells other than DCs, such as macrophages or synovial cells, to solve these problems.
###end p 57
###begin p 58
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 741 745 741 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1222 1224 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 669 675 <span type="species:ncbi:10090">murine</span>
###xml 1076 1080 <span type="species:ncbi:10090">mice</span>
###xml 1318 1322 <span type="species:ncbi:10090">mice</span>
###xml 1424 1427 <span type="species:ncbi:31658">CFA</span>
TLRs have been shown to play a role in the acquired immune responses by promoting cytokine and chemokine production and costimulatory molecule expression. In addition, a recent report showed that MD1, a molecule that forms a complex with RP105, regulated the development of Tregs induced by LPS [38]. We also observed the impaired Treg function in RP105-deficient mice. The Tregs play key roles in the maintenance of immunologic self-tolerance and negative control of a variety of physiological and pathological immune responses [43,44]. The administration of a Treg-depleting anti-CD25 antibody induced an accelerated onset of arthritis and a more severe arthritis in murine CIA [45,46]. In our experiment, the suppressive function of RP105-/- Tregs was impaired when the cells were stimulated with collagen, but not with anti-CD3 antibody. These data suggest that reduced Treg function is not intrinsic but instead is due to insufficient activation when triggered by antigen presented by APCs. Alternatively, the number of CII-specific Tregs is decreased in RP105-deficient mice. It has been shown that the suppressive effect of Tregs is blocked by DCs activated by TLR ligands, such as LPS or CpG, via IL-6 production [47]. Therefore, it is possible that impaired antigen-specific Treg induction in RP105-deficient mice is due to an overproduction of inflammatory cytokines by APCs activated by immunization with CII and CFA.
###end p 58
###begin p 59
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 171 174 <span type="species:ncbi:31658">CFA</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 237 240 <span type="species:ncbi:31658">CFA</span>
###xml 323 326 <span type="species:ncbi:31658">CFA</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 602 605 <span type="species:ncbi:31658">CFA</span>
###xml 712 715 <span type="species:ncbi:31658">CFA</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
Next, we tried to elucidate whether the regulatory role of RP105 in the development of arthritis is exerted only when the disease was induced by active immunization using CFA. If enhanced arthritis development in RP105-deficient mice is CFA-dependent, it can be speculated that the activation signal through TLRs evoked by CFA, which contains heat-killed mycobacteria, is augmented in APCs lacking RP105. However, RP105-deficient mice showed a higher incidence even when arthritis was induced using IFA only, thus indicating that the enhancing effect in arthritis development does not depend solely on CFA. To explain these results, we hypothesized that the signals provided by endogenous TLR ligands other than CFA also made the difference between RP105-deficient and wild-type mice. Recently, various endogenous ligands of TLR4 and TLR2 have been reported. These molecules include fibrinogen degradation products [15], hyaluronan fragments [13,14], fibronectin fragments [48], heparan sulfate [49], high-mobility group box-1 protein [50], and heat shock proteins [10-12]. These molecules have been shown to induce the activation or the release of proinflammatory cytokines from DCs or macrophages. In addition, heat shock proteins, fibrinogen, and degraded hyaluronan are commonly found in inflamed joints. Therefore, it is possible that DCs and synovial macrophages lacking RP105 might be highly activated by these endogenous ligands, thus resulting in the enhanced development of arthritis. However, this hypothesis has yet to be investigated.
###end p 59
###begin p 60
###xml 346 355 346 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
This study has a limitation regarding the specificity of TLRs. Because we used conventional LPS, which might have been contaminated with TLR2 ligands, we could not determine the precise role of TLR4 in our studies. As such, it remains to be investigated which TLR is regulated by RP105 in these models using more specific ligands and whether the in vitro activation and cytokine production from various cells (for example, macrophages and synovial cells) are altered in the absence of RP105.
###end p 60
###begin p 61
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 349 353 345 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 394 401 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 509 511 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 558 562 554 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
RP105 is also expressed in B cells. B cells from RP105-deficient mice are hyporesponsive to LPS, in contrast to DCs, and to lipoproteins [30,31]. Our observation that RP105-deficient mice developed severe arthritis in response to anti-CII antibody and LPS and produced more TNF-alpha in response to LPS indicated that the hyporesponsiveness of RP105-/- B cells might be overcome by other cells in vivo. In addition, RP105-deficient mice were not impaired with respect to T-cell-dependent antibody production [30]. In keeping with this, we observed that RP105-/- mice showed comparable levels of anti-CII antibody in CIA.
###end p 61
###begin p 62
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 268 273 <span type="species:ncbi:9606">human</span>
Several studies have demonstrated the involvement of TLRs in arthritis models. The intra-articular triggering of TLRs led to the joint inflammation [23,24], and TLR2 and TLR4 have been shown to play a critical role in bacterial cell wall-induced arthritis [18,20]. In human RA, TLRs, including TLR2 and TLR4, are expressed in synovial cells and are upregulated by proinflammatory cytokines [5-9]. RA synovial cells have been shown to produce various chemokines after the stimulation with TLR2 ligands [51] and inflammatory cytokines after triggering TLR2 or TLR4 [52]. In addition, the suppression of MyD88 or Mal/TIRAP by transfecting the dominant negative form downregulated the production of cytokines and matrix metalloproteinases from synovial cells [52]. Although these studies emphasize the proinflammatory roles of TLRs and adaptor molecules, the regulatory or anti-inflammatory role of TLR family members is not known. Our data suggest that a potential regulatory mechanism exists in the TLR-TLR ligand system in inflammation.
###end p 62
###begin title 63
Conclusions
###end title 63
###begin p 64
Our study demonstrated that RP105 regulated the cell-mediated immune response by the suppression of APC function and regulatory T-cell development and, as a result, attenuated the development of CIA. Further study is necessary to address the precise interaction between RP105 and various TLRs and the mechanism of regulation in the inflammatory process in the development of arthritis.
###end p 64
###begin title 65
Abbreviations
###end title 65
###begin p 66
###xml 64 67 <span type="species:ncbi:31658">CFA</span>
APC: antigen-presenting cell; cDC: conventional dendritic cell; CFA: complete Freund's adjuvant; CIA: collagen-induced arthritis; CII: type II collagen; DC: dendritic cell; dCII: denatured type II collagen; DMEM: Dulbecco's modified Eagle's medium; ELISA: enzyme-linked immunosorbent assay; IFA: incomplete Freund's adjuvant; IFN-gamma: interferon-gamma; IL: interleukin; LNC: lymph node cell; LPS: lipopolysaccharide; MyD88: myeloid differentiation factor 88; pDC: plasmacytoid dendritic cell; RA: rheumatoid arthritis; TLR: Toll-like receptor; TNF-alpha: tumor necrosis factor-alpha; Treg: regulatory T cell.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
The authors declare that they have no competing interests.
###end p 68
###begin title 69
Authors' contributions
###end title 69
###begin p 70
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
YT carried out the in vivo and in vitro studies. SK carried out the flow cytometric analysis. FM, AO, and KN participated in the design and coordination of the study. MM, HI, and RS participated in the design of the study and the maintenance of the animals. KM provided the animals and gave final approval of the version to be published. All authors read and approved the final manuscript.
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
The authors thank Motoko Fujisaki for animal care and Yumiko Tsugitomi for technical help with histology. This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a grant from Saga Medical School.
###end p 72
###begin article-title 73
Innate immune recognition
###end article-title 73
###begin article-title 74
The interleukin-1/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products
###end article-title 74
###begin article-title 75
Toll-like receptor control of the adaptive immune responses
###end article-title 75
###begin article-title 76
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense
###end article-title 76
###begin article-title 77
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis
###end article-title 77
###begin article-title 78
Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium
###end article-title 78
###begin article-title 79
Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma
###end article-title 79
###begin article-title 80
The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells
###end article-title 80
###begin article-title 81
Increased macrophage activation mediated through Toll-like receptors in rheumatoid arthritis
###end article-title 81
###begin article-title 82
Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex
###end article-title 82
###begin article-title 83
Novel signal transduction pathway utilized by extracellular HSP70. Role of Toll-like receptor (TLR) 2 and TLR4
###end article-title 83
###begin article-title 84
Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis
###end article-title 84
###begin article-title 85
Oligosaccharides of hyaluronan activates dendritic cells via Toll-like receptor 4
###end article-title 85
###begin article-title 86
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2
###end article-title 86
###begin article-title 87
Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4
###end article-title 87
###begin article-title 88
Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp) 70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming
###end article-title 88
###begin article-title 89
Dendritic cells Fcgamma receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis
###end article-title 89
###begin article-title 90
Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88
###end article-title 90
###begin article-title 91
Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS
###end article-title 91
###begin article-title 92
###xml 180 184 <span type="species:ncbi:10090">mice</span>
Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of Toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice
###end article-title 92
###begin article-title 93
MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals
###end article-title 93
###begin article-title 94
Toll-like receptor 4 induced Fcgamma R expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: Toll-like receptor 4 largely regulates Fcgamma R expression by interleukin 10
###end article-title 94
###begin article-title 95
Intra-articulary localized bacterial DNA containing CpG motifs induces arthritis
###end article-title 95
###begin article-title 96
Arthritogenic properties of double-stranded (viral) RNA
###end article-title 96
###begin article-title 97
###xml 85 89 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Oligodeoxynucleotides containing CpG motifs can induce T cell-dependent arthritis in rats
###end article-title 97
###begin article-title 98
Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs
###end article-title 98
###begin article-title 99
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsivness of X-linked immunodeficient B cells
###end article-title 99
###begin article-title 100
RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family
###end article-title 100
###begin article-title 101
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression
###end article-title 101
###begin article-title 102
The Toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells
###end article-title 102
###begin article-title 103
The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes
###end article-title 103
###begin article-title 104
B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus
###end article-title 104
###begin article-title 105
###xml 33 41 <span type="species:ncbi:9606">patients</span>
RP105-lacking B cells from lupus patients are responsible for the production of immunoglobulins and autoantibodies
###end article-title 105
###begin article-title 106
Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105
###end article-title 106
###begin article-title 107
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis
###end article-title 107
###begin article-title 108
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice
###end article-title 108
###begin article-title 109
###xml 15 19 <span type="species:ncbi:10090">mice</span>
CD28-deficient mice are highly resistant to collagen-induced arthritis
###end article-title 109
###begin article-title 110
MD1 expression regulates development of regulatory T cells
###end article-title 110
###begin article-title 111
###xml 101 127 97 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis</italic>
###xml 101 127 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tuberculosis
###end article-title 111
###begin article-title 112
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Toll-like receptor 4 plays a protective role in puomonary tuberculosis in mice
###end article-title 112
###begin article-title 113
###xml 47 74 47 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis </italic>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 47 73 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection
###end article-title 113
###begin article-title 114
###xml 57 83 57 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 57 83 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis
###end article-title 114
###begin article-title 115
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 11 13 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 16 18 16 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease
###end article-title 115
###begin article-title 116
Regulatory T cells in the control of immune pathology
###end article-title 116
###begin article-title 117
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis
###end article-title 117
###begin article-title 118
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma
###end article-title 118
###begin article-title 119
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells
###end article-title 119
###begin article-title 120
The extra domain A of fibronectin activates Toll-like receptor 4
###end article-title 120
###begin article-title 121
Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4
###end article-title 121
###begin article-title 122
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein
###end article-title 122
###begin article-title 123
Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands
###end article-title 123
###begin article-title 124
###xml 122 127 <span type="species:ncbi:9606">human</span>
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis
###end article-title 124

